A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea

BACKGROUND: Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). METHODS: This phase III, multicentre, randomised, double-blind, placebo-controlled study (BEL113750; NCT01345253) was con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fengchun, Bae, Sang-Cheol, Bass, Damon, Chu, Myron, Egginton, Sally, Gordon, David, Roth, David A, Zheng, Jie, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867402/
https://www.ncbi.nlm.nih.gov/pubmed/29295825
http://dx.doi.org/10.1136/annrheumdis-2017-211631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867402/
https://www.ncbi.nlm.nih.gov/pubmed/29295825
http://dx.doi.org/10.1136/annrheumdis-2017-211631

Ejemplares similares